Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,585 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT07702955 | Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 85 | Kangabio AUSTRALIA LTD PTYINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04706598 | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment | active not recruiting | Phase 1 / Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05770310 | A Phase I Study Of JS015 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07059221 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer | recruiting | Phase 1 / Phase 2 | 210 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07368127 | A Study of TPD3310 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 112 | TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07620314 | Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713290 | A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 1 | 6 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714798 | Universal STAR-T Cell Injection in Generalized Myasthenia Gravis | not yet recruiting | Phase 1 | 10 | Daishi TianOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | recruiting | Phase 1 | 15 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715747 | A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 128 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05379946 | Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 92 | InventisBio Co., LtdINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06565689 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | recruiting | Phase 1 | 48 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07246707 | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710690 | A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 24 | Neuregen Therapeutics Co., Ltd.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05114759 | A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 176 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 3 | Jul 16, 2026 | clinicaltrials |
| NCT05740202 | A Trial of SHR-7367 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 22 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06555068 | A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 528 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708194 | Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | recruiting | Phase 1 / Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05396300 | A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 58 | Weijia Fang, MDOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07704515 | GKL-006Allo Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 27 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07704866 | A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 120 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT05747729 | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT07472790 | A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma | not yet recruiting | Phase 1 | 15 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07583654 | Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors | recruiting | Phase 1 | 18 | West China HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | not yet recruiting | Phase 1 | 258 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702162 | A Clinical Study of PA5 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 49 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | enrolling by invitation | Phase 1 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07583212 | Phase I Study of HRS-1635 in B-cell Malignancies | recruiting | Phase 1 | 180 | Chengdu Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07636798 | Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697443 | Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | not yet recruiting | Phase 1 / Phase 2 | 306 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698587 | A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 90 | Suzhou Biomissile Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 40 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07617493 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 539 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07695142 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 275 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07697040 | Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC | not yet recruiting | Phase 1 | 12 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05061628 | The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05415475 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06464965 | Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer | completed | Phase 1 | 9 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 168 | BeOne MedicinesINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT07692750 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 56 | Zhejiang Cancer HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04773951 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials